Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
CCOP - Ochsner
mi
from
New Orleans, LA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
CCOP - Ochsner
mi
from
New Orleans, LA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
St. Agnes Hospital Cancer Center
mi
from
Baltimore, MD
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
St. Agnes Hospital Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Cancer Institute at St. Joseph Medical Center
mi
from
Towson, MD
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Cancer Institute at St. Joseph Medical Center
mi
from
Towson, MD
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Boston University Cancer Research Center
mi
from
Boston, MA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Adams Cancer Center
mi
from
Gettysburg, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Cherry Tree Cancer Center
mi
from
Hanover, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Cherry Tree Cancer Center
mi
from
Hanover, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Cancer Center of Paoli Memorial Hospital
mi
from
Paoli, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Cancer Center of Paoli Memorial Hospital
mi
from
Paoli, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
El Cajon, CA
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
El Cajon, CA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Gilroy, CA
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Gilroy, CA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Daytona Beach, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Holiday, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Holiday, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Lynn Haven, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Lynn Haven, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Stuart, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Stuart, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Stockbridge, GA
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Shreveport, LA
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Saint Louis Park, MN
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Kansas City, MO
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Berlin, NJ
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Berlin, NJ
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Houston, TX
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Houston, TX
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
mi
from
Bruxelles,
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
mi
from
Bruxelles,
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Winter Park, FL
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Newnan, GA
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials